All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Navigating Personalized Approaches With Radiation Therapy for Early-Stage Breast Cancer

April 26th 2024

Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy in early-stage breast cancer.

DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer

April 26th 2024

The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

April 25th 2024

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study

April 25th 2024

A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

April 25th 2024

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024

Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.

Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma

April 25th 2024

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer

April 25th 2024

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

Toripalimab NDA Under Review in Hong Kong for Nasopharyngeal Carcinoma

April 25th 2024

A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024

HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.

Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial Cancer

April 25th 2024

Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology

April 24th 2024

Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC

April 24th 2024

Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.

International Pancreatic Cancer Screening Program Displays Practicality

April 24th 2024

The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.

Enzalutamide Receives Go Ahead From European Commission in nmHSPC

April 24th 2024

The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.

What If We Could Eliminate a Major Gastric Cancer Risk Factor?

April 24th 2024

A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor for gastric cancer.

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024

The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.

HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC

April 24th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024

Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.